BMS in vivo study director joins Apexigen to lead antibody discovery

Bahjat will lead Apexigen’s preclinical development of its immuno-oncology pipeline and support its APX005M program. (Pixabay)

Frances Rena Bahjat, Bristol-Myers Squibb’s former senior director of in vivo studies, has joined Apexigen in the newly created role of vice president for discovery research.

Bahjat will lead San Carlos, California-based Apexigen’s preclinical development of its immuno-oncology pipeline, and support its lead program for APX005M, a CD40 agonist currently undergoing a phase 2 trial in collaboration with the University of California, San Francisco.

At BMS, she oversaw biologics discovery pharmacology and in vivo antibody discovery operations at the company’s nearby Redwood City facility.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Rena has significant experience in immunology and pharmaceutical research and development, including the discovery of numerous drug candidates across a diverse array of target classes and therapeutic areas,” President and CEO Xiaodong Yang said in a statement.

Before joining BMS, Bahjat was as an assistant professor at Oregon Health & Sciences University, where she conducted NIH-funded basic and translational research, as well as preclinical development of agonist therapeutics.

She has also served as associate director of pharmacology at Rigel Pharmaceuticals—where she developed kinase inhibitors for cancer, allergies and autoimmune diseases, including Tavalisse for chronic immune thrombocytopenia—and has held positions at Oncovir, Corgentech-AlgoRX, Nereus Pharmaceuticals and Nuvelo, now known as Arca Biopharma.

Apexigen’s discovery platform, APXiMAB, focuses on rabbit monoclonal antibodies and mutational lineage guided humanization, and has produced seven candidates for clinical development.

The company announced its collaboration with UCSF in October 2017. The phase 2 trial plans to evaluate APX005M in combination with chemotherapy and radiation therapy in patients with resectable esophageal and gastro-esophageal junction cancers.

In addition, Apexigen launched a phase 1b/2 open-label study last year combining APX005M with BMS’ Opdivo in pancreatic cancer, through a collaboration with the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute. The two companies are also studying the combination in non-small cell lung cancer and metastatic melanoma.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.